Scienture Secures Patent for High-Dose Naloxone Spray, Extending IP Protection to 2041
Event summary
- Scienture Holdings received a U.S. patent for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026, expiring February 5, 2041.
- The patent was originally issued to Summit Biosciences, a subsidiary of Kindeva Drug Delivery, under a 2025 commercialization agreement.
- REZENOPY™ is the highest FDA-approved dose per nasal spray for naloxone, targeting the $141 million U.S. naloxone market with 9.4 million units sold annually.
- Scienture plans to launch REZENOPY™ commercially in mid-July 2026, with Summit handling manufacturing and Scienture managing U.S. distribution.
The big picture
The patent extension solidifies Scienture's competitive edge in the naloxone market, particularly as opioid overdoses involving potent synthetic opioids rise. With IP protection secured through 2041, Scienture aims to leverage its commercial infrastructure to capture a significant share of the $141 million U.S. naloxone market. The strategic partnership with Summit Biosciences ensures manufacturing continuity, while Scienture focuses on distribution and marketing.
What we're watching
- Market Penetration
- How Scienture will position REZENOPY™ against existing naloxone products in a market dominated by lower-dose alternatives.
- Regulatory Dynamics
- Whether the FDA's approval of higher-dose naloxone will drive broader adoption in emergency settings.
- Execution Risk
- The pace at which Scienture can scale commercial operations to capitalize on the patent-protected product.
Related topics